File downloaded on 2026-11-08
Source URL: https://medicines.health.europa.eu/veterinary/en/600000047944

Baycox Multi 50 mg/ml oral suspension for Cattle, Pigs and Sheep

Authorised

- Toltrazuril

Product identification

Medicine name:
Baycox Multi 50 mg/ml oral suspension for Cattle, Pigs and Sheep

Active substance:
Toltrazuril

Target species:
Cattle
Sheep
Pig

Route of administration:
Oral use

Product details

Active substance and strength:
Toltrazuril
50.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:
Oral suspension

Withdrawal period by route of administration:

Oral use:

- **Cattle**
  - Meat and offal. 63 day
  - Milk. no withdrawal period

Not authorised for use in animals producing milk for human consumption.

- **Sheep**
  - Meat and offal. 42 day
  - Milk. no withdrawal period

Not authorised for use in animals producing milk for human consumption.

- **Pig**
  - Meat and offal. 77 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QP51BC01

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Lithuania

Available in:
Lithuania

Package description:

1000 ml high density polyethylene bottles closed with polypropylene screw caps.
250 ml high density polyethylene bottles closed with polypropylene screw caps.
100 ml high density polyethylene bottles closed with polypropylene screw caps.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
Elanco Animal Health GmbH

Marketing authorisation date:
8/11/2016

Manufacturing sites for batch release:
KVP Pharma+Veterinaer Produkte GmbH

Responsible authority:
State Food And Veterinary Service

Authorisation number:
This information is not available for this product.

Date of authorisation status change:
24/07/2025

Reference member state:
Ireland

Procedure number:
IE/V/0360/001

Concerned member states:
Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland France Germany Greece Hungary Iceland Italy Latvia Lithuania

Luxembourg Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 6/07/2025
Updated on: 13/03/2026
Download

Summary of Product Characteristics